Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 13, 2024, reporting an event that occurred on July 25, 2024. The company is a Delaware corporation with its principal executive offices in Houston, Texas, and its common stock trades on The Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a current report regarding a specific corporate event rather than a periodic financial statement.
Material Changes
The material change reported is the filing of a Prospectus Supplement on July 25, 2024, to an effective Form S-3 Registration Statement (File No. 333-266589). This supplement covers the registered offering of up to $335,921 of shares of common stock (par value $0.0001 per share) pursuant to an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., dated February 5, 2021.
Guidance, Outlook, and Risks
The filing does not provide management guidance, outlook, or specific risk factors beyond the standard disclosure of the securities offering. It includes a legal opinion from Hogan Lovells US LLP regarding the validity of the shares being registered, which is attached as Exhibit 5.1.
Investor Verification Checklist
- Verify the company name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Confirm the total offering amount under the At-the-Market agreement is $335,921.
- Review the attached Exhibit 5.1 for the legal opinion on share validity.
- Check the effective date of the underlying Form S-3 Registration Statement (August 16, 2022).